Does the media refer more to FBIO or IKT?

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Inhibikase Therapeutics and 1 mentions for Fortress Biotech. Inhibikase Therapeutics' average media sentiment score of 0.51 beat Fortress Biotech's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ACB or FBIO?

Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 737.44%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to ACB or FBIO?

In the previous week, Aurora Cannabis had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Aurora Cannabis and 1 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.81 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Negative Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FBIO or PALI?

In the previous week, Palisade Bio had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 5 mentions for Palisade Bio and 1 mentions for Fortress Biotech. Palisade Bio's average media sentiment score of 0.64 beat Fortress Biotech's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FBIO or SIGA?

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 737.44%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Fortress Biotech is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor FBIO or SIGA?

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Siga Technologies' average media sentiment score of 1.76 beat Fortress Biotech's score of 0.00 indicating that Siga Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Siga Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Fortress Biotech (FBIO) Competitors

$2.03 -0.04 (-1.93%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.05 +0.02 (+0.94%)

As of 10/2/2026 07:52 PM Eastern

Compare

FBIO vs. IKT, AMRN, ACB, PALI, and SIGA

Should you buy Fortress Biotech stock or one of its competitors? Fortress Biotech's main competitors and comparable companies include Inhibikase Therapeutics (IKT), Amarin (AMRN), Aurora Cannabis (ACB), Palisade Bio (PALI), and Siga Technologies (SIGA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Fortress Biotech compare to Inhibikase Therapeutics?

Fortress Biotech (NASDAQ:FBIO) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Fortress Biotech has a net margin of 163.32% compared to Inhibikase Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Fortress Biotech has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.07	$6.82M	$2.64	0.77
Inhibikase Therapeutics	$260K	1,073.38	-$48.26M	-$0.43	N/A

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Inhibikase Therapeutics and 1 mentions for Fortress Biotech. Inhibikase Therapeutics' average media sentiment score of 0.51 beat Fortress Biotech's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 737.44%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 170.00%. Given Fortress Biotech's higher possible upside, equities analysts plainly believe Fortress Biotech is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Fortress Biotech has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Summary

Fortress Biotech beats Inhibikase Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Amarin?

Amarin (NASDAQ:AMRN) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Fortress Biotech has a net margin of 163.32% compared to Amarin's net margin of -14.56%. Fortress Biotech's return on equity of 83.47% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Fortress Biotech	163.32%	83.47%	42.98%

Amarin currently has a consensus price target of $13.00, indicating a potential upside of 5.26%. Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 737.44%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.22	-$38.80M	-$0.99	N/A
Fortress Biotech	$63.26M	1.07	$6.82M	$2.64	0.77

In the previous week, Fortress Biotech had 1 more articles in the media than Amarin. MarketBeat recorded 1 mentions for Fortress Biotech and 0 mentions for Amarin. Amarin's average media sentiment score of 1.88 beat Fortress Biotech's score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company	Overall Sentiment
Amarin	Very Positive
Fortress Biotech	Neutral

22.3% of Amarin shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amarin has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Summary

Fortress Biotech beats Amarin on 13 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Fortress Biotech has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$314.07M	0.82	-$88.13M	-$1.41	N/A
Fortress Biotech	$63.26M	1.07	$6.82M	$2.64	0.77

In the previous week, Aurora Cannabis had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Aurora Cannabis and 1 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.81 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Negative
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 737.44%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aurora Cannabis has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

Fortress Biotech has a net margin of 163.32% compared to Aurora Cannabis' net margin of -32.26%. Fortress Biotech's return on equity of 83.47% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Fortress Biotech	163.32%	83.47%	42.98%

Summary

Fortress Biotech beats Aurora Cannabis on 13 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Palisade Bio?

Fortress Biotech (NASDAQ:FBIO) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Fortress Biotech presently has a consensus target price of $17.00, suggesting a potential upside of 737.44%. Palisade Bio has a consensus target price of $9.83, suggesting a potential upside of 582.87%. Given Fortress Biotech's higher possible upside, equities analysts clearly believe Fortress Biotech is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fortress Biotech has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.07	$6.82M	$2.64	0.77
Palisade Bio	$250K	1,003.80	-$16.78M	-$0.48	N/A

Fortress Biotech has a net margin of 163.32% compared to Palisade Bio's net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Palisade Bio	N/A	-33.47%	-31.79%

In the previous week, Palisade Bio had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 5 mentions for Palisade Bio and 1 mentions for Fortress Biotech. Palisade Bio's average media sentiment score of 0.64 beat Fortress Biotech's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Summary

Fortress Biotech beats Palisade Bio on 10 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Siga Technologies?

Fortress Biotech (NASDAQ:FBIO) and Siga Technologies (NASDAQ:SIGA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Siga Technologies has higher revenue and earnings than Fortress Biotech. Siga Technologies is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.07	$6.82M	$2.64	0.77
Siga Technologies	$94.57M	2.57	$23.28M	-$0.05	N/A

Fortress Biotech has a net margin of 163.32% compared to Siga Technologies' net margin of -5.19%. Fortress Biotech's return on equity of 83.47% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Siga Technologies	-5.19%	-1.55%	-1.32%

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Siga Technologies' average media sentiment score of 1.76 beat Fortress Biotech's score of 0.00 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Siga Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 737.44%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Fortress Biotech is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Fortress Biotech has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 2.7% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Fortress Biotech beats Siga Technologies on 11 of the 15 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBIO vs. The Competition

Export

Metric	Fortress Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$67.70M	$12.24B	$7.16B	$13.28B
Dividend Yield	N/A	2.64%	2.54%	17.32%
P/E Ratio	0.77	660.22	215.53	21.44
Price / Sales	1.07	751.63	609.31	92.00
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	1.02	10.46	10.93	6.31
Net Income	$6.82M	$2.84B	$3.51B	$362.16M
7 Day Performance	-10.96%	-1.57%	-2.00%	-1.66%
1 Month Performance	-25.09%	-5.67%	-6.15%	-4.50%
1 Year Performance	-26.18%	-4.73%	7.44%	2.06%

Fortress Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBIO Fortress Biotech	2.309 of 5 stars	$2.03 -1.9%	$17.00 +737.4%	-27.5%	$67.70M	$63.26M	0.77	78	News Coverage
IKT Inhibikase Therapeutics	2.4388 of 5 stars	$2.02 -1.3%	$5.40 +166.8%	+22.0%	$283.27M	$260K	N/A	35	News Coverage
AMRN Amarin	1.1588 of 5 stars	$13.23 -0.2%	$13.00 -1.7%	-26.2%	$280.16M	$213.65M	N/A	80	Positive News Gap Up
ACB Aurora Cannabis	0.966 of 5 stars	$4.09 -0.1%	N/A	-31.0%	$264.81M	$247.82M	N/A	1,028	Analyst Upgrade
PALI Palisade Bio	2.9391 of 5 stars	$1.49 -1.0%	$9.83 +562.2%	-15.3%	$258.79M	$250K	N/A	14	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBIO) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortress Biotech (FBIO) Competitors

FBIO vs. IKT, AMRN, ACB, PALI, and SIGA

How does Fortress Biotech compare to Inhibikase Therapeutics?

Summary

How does Fortress Biotech compare to Amarin?

Summary

How does Fortress Biotech compare to Aurora Cannabis?

Summary

How does Fortress Biotech compare to Palisade Bio?

Summary

How does Fortress Biotech compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortress Biotech (FBIO) Competitors

FBIO vs. IKT, AMRN, ACB, PALI, and SIGA

How does Fortress Biotech compare to Inhibikase Therapeutics?

Is FBIO or IKT more profitable?

Which has better valuation and earnings, FBIO or IKT?

Does the media refer more to FBIO or IKT?

Do analysts rate FBIO or IKT?

Do insiders & institutionals believe in FBIO or IKT?

Which has more volatility and risk, FBIO or IKT?

Summary

How does Fortress Biotech compare to Amarin?

Is AMRN or FBIO more profitable?

Do analysts recommend AMRN or FBIO?

Which has preferable earnings & valuation, AMRN or FBIO?

Does the media refer more to AMRN or FBIO?

Do institutionals and insiders believe in AMRN or FBIO?

Which has more risk & volatility, AMRN or FBIO?

Summary

How does Fortress Biotech compare to Aurora Cannabis?

Which has stronger valuation & earnings, ACB or FBIO?

Does the media refer more to ACB or FBIO?

Do institutionals & insiders believe in ACB or FBIO?

Do analysts recommend ACB or FBIO?

Which has more risk and volatility, ACB or FBIO?

Is ACB or FBIO more profitable?

Summary

How does Fortress Biotech compare to Palisade Bio?

Do analysts recommend FBIO or PALI?

Do institutionals and insiders hold more shares of FBIO or PALI?

Which has preferable valuation & earnings, FBIO or PALI?

Is FBIO or PALI more profitable?

Does the media favor FBIO or PALI?

Which has more volatility and risk, FBIO or PALI?

Summary

How does Fortress Biotech compare to Siga Technologies?

Which has stronger valuation and earnings, FBIO or SIGA?

Is FBIO or SIGA more profitable?

Does the media favor FBIO or SIGA?

Do analysts rate FBIO or SIGA?

Which has more volatility and risk, FBIO or SIGA?

Do institutionals & insiders have more ownership in FBIO or SIGA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools